Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VII. Present and future of technologies for production of CAR cell therapies

Chimeric Antigen Receptor T (CAR-T) cells are certainly an important therapy for patients with relapsed and/or refractory hematologic malignancies. Currently, there are five CAR-T cell products approved by the FDA but several research groups and/or biopharmaceutical companies are encouraged to devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, Rodrigo Nalio, Picanço-Castro, Virginia, Oliveira, Theo Gremen M., Mendrone, Alfredo, De Santis, Gil Cunha, Bonamino, Martin Hernan, Rocha, Vanderson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606694/
https://www.ncbi.nlm.nih.gov/pubmed/34794797
http://dx.doi.org/10.1016/j.htct.2021.09.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606694/
https://www.ncbi.nlm.nih.gov/pubmed/34794797
http://dx.doi.org/10.1016/j.htct.2021.09.007

Ejemplares similares